Current Edition

PharmaLex strengthens its commercial organization

The appointment of Sébastien Schmitt will further consolidate
PharmaLex’s commercial offerings for our clients.

PharmaLex Group, a leading provider of specialized services for pharma, biotech and medical device industries worldwide, is pleased to welcome Sébastien Schmitt as a valuable addition to our senior management team.

Sébastien joins PharmaLex as Chief Commercial Officer where he will oversee all aspects of PharmaLex commercial activities, ensuring that our clients benefit from a truly integrated service offering.

Through his role, he will ensure that PharmaLex further strengthens the commercial fundamentals, strategy, operations and a team dynamic that will be designed to grow with our clients’ needs and provide the best possible solution globally and regionally. Besides this key focus, he will also develop the PharmaLex Swiss country organization as its Managing Director. His vast experience in sales and marketing and his solid track record in delivering tailored service solutions, especially to multi-national clients, will be a timely enrichment to our organization.

Sébastien joins PharmaLex following nearly a decade with ProductLife Group, where he headed the delivery and commercial organization.

“I am very excited to join a growing organization like PharmaLex”, explained Sébastien. “Their reputation as a leader in specialized services for the life science industry is well known and their global footprint presents excellent opportunities to provide real added value to their clients”, he commented.

“We are extremely pleased that Sébastien is joining us to head and further shape our commercial organisation. His ability to deliver customer-focused and results-oriented solutions was key during the selection process”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “Furthermore, we have seen a very positive development in the entire DACH region and strengthening our location in Switzerland will be of particular strategic importance, ensuring that our services can be expanded to the hotspot of the Swiss pharmaceutical industry.”